Targeting effective blood pressure control with angiotensin receptor blockers

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Nephrology

Background:

• Angiotensin receptor blockers (ARBs) are a cornerstone antihypertensive therapy due to their efficacy, tolerability, and organ-protective benefits.
• Individual ARBs exhibit varying degrees of antihypertensive efficacy, potentially impacting clinical outcomes.
• Optimizing blood pressure (BP) control with ARBs is crucial and can be achieved through various strategies.

Purpose of the Study:

• To review strategies for maximizing antihypertensive efficacy with ARBs.
• To compare the efficacy of different ARBs and combination therapies.
• To highlight the importance of compound-specific data for ARB selection.

Main Methods:

• Review of clinical studies and pharmacological data on ARB efficacy.
• Comparison of antihypertensive effects of ARBs against other classes (e.g., amlodipine).
• Evaluation of dose-escalation strategies and fixed-dose combinations with hydrochlorothiazide (HCTZ).

Main Results:

• Newer ARBs (irbesartan, candesartan, telmisartan, olmesartan) show comparable or superior efficacy to amlodipine and older ARBs like losartan and valsartan.
• Increasing the dose of certain ARBs (e.g., valsartan) may enhance BP reduction, requiring further clinical validation.
• Fixed-dose combinations of ARBs with HCTZ significantly augment antihypertensive effects, offering an additional level of BP control.

Conclusions:

• Differences in antihypertensive efficacy among ARBs persist, even in combination therapies.
• The most potent ARBs, particularly in combination with HCTZ, provide superior blood pressure control.
• Future ARB utilization will increasingly rely on compound-specific data regarding both antihypertensive and pleiotropic effects.